Optimal delivery of minocycline to the brain

Implication for human studies of acute neuroprotection

Susan C. Fagan, David J. Edwards, Cesar V. Borlongan, Lin Xu, Ankur Arora, Giora Feuerstein, David C Hess

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.

Original languageEnglish (US)
Pages (from-to)248-251
Number of pages4
JournalExperimental Neurology
Volume186
Issue number2
DOIs
StatePublished - Apr 1 2004

Fingerprint

Minocycline
Brain
Brain Diseases
Neuroprotective Agents
Brain Injuries
Neuroprotection

Keywords

  • Blood-brain barrier
  • Dose
  • Intraperitoneal
  • Minocycline
  • Neuroprotection
  • Pharmacokinetics

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Optimal delivery of minocycline to the brain : Implication for human studies of acute neuroprotection. / Fagan, Susan C.; Edwards, David J.; Borlongan, Cesar V.; Xu, Lin; Arora, Ankur; Feuerstein, Giora; Hess, David C.

In: Experimental Neurology, Vol. 186, No. 2, 01.04.2004, p. 248-251.

Research output: Contribution to journalArticle

Fagan, Susan C. ; Edwards, David J. ; Borlongan, Cesar V. ; Xu, Lin ; Arora, Ankur ; Feuerstein, Giora ; Hess, David C. / Optimal delivery of minocycline to the brain : Implication for human studies of acute neuroprotection. In: Experimental Neurology. 2004 ; Vol. 186, No. 2. pp. 248-251.
@article{737607783f5848a08572d89ea2aee32f,
title = "Optimal delivery of minocycline to the brain: Implication for human studies of acute neuroprotection",
abstract = "Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.",
keywords = "Blood-brain barrier, Dose, Intraperitoneal, Minocycline, Neuroprotection, Pharmacokinetics",
author = "Fagan, {Susan C.} and Edwards, {David J.} and Borlongan, {Cesar V.} and Lin Xu and Ankur Arora and Giora Feuerstein and Hess, {David C}",
year = "2004",
month = "4",
day = "1",
doi = "10.1016/j.expneurol.2003.12.006",
language = "English (US)",
volume = "186",
pages = "248--251",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Optimal delivery of minocycline to the brain

T2 - Implication for human studies of acute neuroprotection

AU - Fagan, Susan C.

AU - Edwards, David J.

AU - Borlongan, Cesar V.

AU - Xu, Lin

AU - Arora, Ankur

AU - Feuerstein, Giora

AU - Hess, David C

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.

AB - Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.

KW - Blood-brain barrier

KW - Dose

KW - Intraperitoneal

KW - Minocycline

KW - Neuroprotection

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=1542722933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542722933&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2003.12.006

DO - 10.1016/j.expneurol.2003.12.006

M3 - Article

VL - 186

SP - 248

EP - 251

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -